17 | Perry HD | I | Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction | Cornea. 2006 Feb;25(2):171–175 | Y | Y | Y | Y | Topical 0.05% cyclosporin versus artificial tears | 3 months | Prospective | Y | Y-double | Y | n = 33 enrolled, n = 16 (12 completed) treatment (Tx), n = 17 (14 completed) placebo | 18 and older, average age, not given |
21 | Schechter BA | I | Efficacy of topical cyclosporine for the treatment of ocular rosacea | Adv Ther. 2009;26(6):651–659 | Y | Y | Y | Y | Topical 0.05% cyclosporine versus artificial tears | 3 months | Prospective | Y | Y-double | Y | n = 37, n = 21 Tx, n = 16 placebo | 18 and older, average age, ∼72.6 y |
26 | Yoo SE | I | The effect of low-dose doxycycline therapy in chronic meibomian gland dysfunction | Korean J Ophthalmol. 2005;19(4):258–263 | Y | Y | Y | Y | Systemic doxycycline 200 or 20 mg twice a day or placebo | 1 month | Prospective | Y | Y-patient | Y | n = 150 enrolled (n = 139 completed), n = 50 high dose, n = 50 low dose, n = 50 placebo | 18 and older, average age, ∼47.2 y |
8 | Goto E | I–II | Low-concentration homogenized castor oil eye drops for noninflamed obstructive meibomian gland dysfunction | Ophthalmology. 2002;109(11):2030–2035 | Y | Y | Y | Y | Castor oil eye drop versus artificial tears | 2 week washout, 1 month | Prospective, cross-over | Y | Y-double | Y | n = 20, 10 per group | 18 and older, average age, 52.1 y |
20 | Rubin M | I–II | Efficacy of topical cyclosporin 0.05% in the treatment of posterior blepharitis | J Ocul Pharmacol Ther 2006;22:47–53 | Y | Y | Y | Y | Topical 0.05% cyclosporin versus topical 0.3% tobramycin/0.1% dexamethasone | 3 months | Prospective | Y | N | N | n = 30, 15 per group | 18 and older, average age, ∼51 y |
10 | Luchs J | II | Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis. | Adv Ther. 2008;25:858–870 | Y | Y | Y | Y | Topical azithromycin 1% and hot compresses versus hot compresses alone | 2 weeks | Prospective | Y | N | Y | n = 21, n = 11 Tx and n = 10 placebo | 18 and older, average age, 63.7 y |
12 | Matsumoto Y | II | The evaluation of the treatment response in obstructive meibomian gland disease by in vivo laser confocal microscopy | Graefes Arch Clin Exp Ophthalmol. 2009;247(6):821–829 | Y | Y | Y | Y | Lid hygiene, topical nonpreserved artificial tears, and 0.1% sodium hyaluronate eye drops, topical 0.5% levofloxacin, topical 0.1% fluorometholone, oral minocycline 100 mg twice a day versus lid hygiene, topical nonpreserved artificial tears and 0.1% sodium hyaluronate drops | 12 weeks | Prospective | N | N | Y | n = 27, n = 16 Tx, n = 11 control | 18 and older, average age, ∼65 y |
15 | Olson MC | II | Increase in tear film lipid layer thickness following treatment with warm compresses in patients with meibomian gland dysfunction | Eye Contact Lens. 2003;29(2):96–99 | Y | Y | Y | Y | Heated compress over experimental eye versus room temperature compress over control eye | 5, 15, 30 minutes following application (same day) | Prospective | Y (contralateral eye) | N | Y | n = 20 | range, 26–59 y |
16 | Paugh JR | II | Meibomian therapy in problematic contact lens wear | Optom Vis Sci. 1990;67(11):803–806 | Y | Y | Y | Y | Lid hygiene, warm compresses twice daily for 2 weeks in one eye | 2 weeks | Prospective | Y (contralateral eye) | Y-examiner | Y | n = 21 | range, 22–33 y |
18 | Pinna A | II | Effect of oral linoleic and gamma-linolenic acid on meibomian gland dysfunction | Cornea. 2007;26(3):260–264 | Y | Y | Y | Y | Oral linoleic acid and γ-linolenic acid once daily versus eyelid hygiene (warm eyelid compresses, eyelid massage, and eyelid margin scrubbing) versus both treatments | 6 months | Prospective | Y | Y-examiner | Y | n = 57 (49 completed), 19 per group | 18 and older, average age, 50 y |
19 | Romero JM | II | Conservative treatment of meibomian gland dysfunction | Eye Contact Lens. 2004;30(1):14–19 | Y | Y | Y | Y | Lid hygiene, warm saline soaks, and non-preserved AT four times per day for 2 weeks and then twice per day for 4 weeks | 6 weeks | Prospective | N | Y-photo grader | N | n = 37 enrolled (26 completed) | 18 and older, average age, 57 y |
24 | Souchier M | II | Changes in meibomian fatty acids and clinical signs in patients with meibomian gland dysfunction after minocycline treatment | Br J Ophthalmol. 92(6):819–822 | Y | Y | Y | Y | Lid hygiene versus oral minocycline 50 mg (patients nonresponsive to compress therapy received minocycline) | 8 weeks | Prospective | N | N | Y | n = 20 patients, 10 per group | 18 and older, average age, 66 y |
25 | Yalcin E | II | N-acetylcysteine in chronic blepharitis | Cornea. 2002;21:164–168 | Y | Y | Y | Y | Topical steroid, topical antibiotic, artificial tears, warm compress, and oral n-acetylcysteine versus topical steroid, topical antibiotic, artificial tears, warm compress | 3 months | Prospective | N | N | Y | n = 40, n = 22 Tx, n = 18 control | 18 and older, average age, ∼43 y |
14 | Mori A | II–III | Disposable eyelid-warming device for the treatment of meibomian gland dysfunction | Jpn J Ophthalmol. 203;47(6):578–586 | Y | Y | Y | Y | Application of Eye Warmer lid warming device versus untreated control | 2 weeks | Prospective | N | N (only interferometry grader was masked) | Y | n = 25 (17 treated, 8 untreated) | 18 and older, average age, 53.6 y |
1 | Albietz JM | III | Effect of antibacterial honey on the ocular flora in tear deficiency and meibomian gland disease | Cornea. 2006;25:1012–1019 | Y | Y | N | N | Topical antibacterial honey | 3 months | Prospective | N | N | Y | n = 84 (49 completed), of those enrolled 15 MGD and 20 MGD with tear deficiency | 18 and older, average age, ∼59 y |
2 | Blackie CA | III | Inner eyelid surface temperature as a function of warm compress methodology | Optom Vis Sci. 2008;85(8):675–683 | Y | Y | N | Y | External heat (warm compresses in several different ways) | Same day study | Same day study | Y (contralateral eye) | N | Y | n = 32 normal patients, group A (n = 10), B (n = 10) and C (n = 12) | 18 and older, average age, 34.7 y |
3 | Cetinkaya A | III | Pediatric ocular acne rosacea: long-term treatment with systemic antibiotics | Am J Ophthalmol. 2006;142(5):816–821 | Y (case series) | Y | Y | N | Four pediatric cases: oral erythromycin or oral doxycycline in combination with topical methyl prednisolone and tobramycin | 12–36 months | Retrospective case series | N | N | N | n = 4 | range, 4–12 y |
4 | Dougherty JM | III | The role of tetracycline in chronic blepharitis. Inhibition of lipase production in staphylococci | Invest Ophthalmol Vis Sci. 1991;32(11):2970–2975 | Y (clinical samples, no direct patient treatment) | N | N | N | Tetracycline solution incubated with tetracycline-sensitive strains (Staphylococcus epidermidis and Staphylococcus Aureus) and tetracycline-resistant strains (S. Epidermidis and S. Aureus) | 24 hours | Retrospective, sample collection | N | N | N | MKC n = 2 samples (isolates), Staphylococcus blepharitis, 2 samples (isolates) | Not defined |
5 | Epstein GA | III | Combined excision and drainage with intralesional corticosteroid injection in the treatment of chronic chalazia | Arch Ophthalmol. 1988;106(4):514–516 | Y | Y | Y | Y | Initial warm eyelid soaks for chronic chalazia, eyelid cleaning, topical antibiotic-steroid combination. If no improvement within 2 weeks, surgical excision versus surgical excision and intratarsal injection of triamcinolone | 6 weeks | Initially retrospective, second part prospective | N | N | N | n = 298, first 146 patients: 88 surgery only, 58 surgery and steroids in combination. Additionally 152 patients with combined treatment. | range, 6–88 y, most >50 y |
6 | Goto E | III | Improvement of tear stability following warm compression in patients with meibomian gland dysfunction | Adv Exp Med Biol. 2002;506:1149–1152 | Y | Y | Y | N | Warm compress therapy with a warm steam eye cup device applied for 5 minutes | Same day study | Same day study | N | N | N | n = 6 | 18 and older, average age, 45.8 y |
7 | Goto E | III | Treatment of non-inflamed obstructive meibomian gland dysfunction by an infrared warm compression device | Br J Ophthalmol, 2002;86(12):1403–1407 | Y | Y | Y | N | Infrared warm compression device | 2 weeks | Prospective | N | N | N | n = 37 | 18 and older, average age, ∼55 y |
9 | Ishida R | III | Tear film with “Orgahexa EyeMasks” in patients with meibomian gland dysfunction | Optom Vis Sci. 2008;85(8):684–691 | Y | Y | Y | N | Orgahexa EyeMask eye warmer mask | 2 weeks | Prospective | N | N | Y | n = 42, n = 20 Tx, n = 22 control | 18 and older, average age, 54.5 y |
11 | Matsumoto Y | III | Efficacy of a new warm moist air device on tear functions of patients with simple meibomian gland dysfunction | Cornea. 200625(6):644–650 | Y | Y | Y | Y | Steam warmer four times daily versus traditional warm compresses twice daily | 2 weeks | Prospective | N | N | Y | n = 35, n = 15 MGD, n = 20 control | 18 and older, average age, ∼58.8 y |
13 | Meisler DM | III | Oral erythromycin treatment for childhood blepharokeratitis | J AAPOS. 2000;4(6):379–380 | Y (case series) | Y | Y | N | Oral erythromycin, varying dose starting at 30 to 250 mg twice daily, depending on severity of disease, lid scrubbing twice a day | Up to 12 months | Prospective case series | N | N | N | n = 5 | range, 4–9 y |
22 | Shine WE | III | Minocycline effect on meibomian gland lipids in meibomianitis patients | Exp Eye Res. 2003;76(4):417–420 | Y | Y | Y | N | Oral minocycline 50 mg/daily for 2 weeks followed by 100 mg/daily | 3 months on Tx, 3 months off Tx | Prospective | N | N | N | n = 10 | N/A |
23 | Song CH | III | Enhanced secretory group II PLA2 activity in the tears of chronic blepharitis patients | Invest Ophthalmol Vis Sci. 1999;40(11):2744–2748 | 7N | N | N | N | No treatment, normal tear PLA2 compared with blepharitis including MGD | Same day study | Same day study | N | N | N | n = 46, chronic blepharitis n = 36, controls n = 10 | range, 30–40 y |